Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
Influenza Other Respir Viruses
; 18(5): e13294, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38716791
ABSTRACT
BACKGROUND:
Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.METHODS:
Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.RESULTS:
We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Infecções por Vírus Respiratório Sincicial
/
Hospitalização
Limite:
Female
/
Humans
/
Infant
/
Male
/
Newborn
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article